Clinical Trial Update: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression [Phase 2]

View source ↗

Summary

Phase 2 trial assessing tamoxifen in well-differentiated neuroendocrine tumors with estrogen or progesterone receptor positivity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Well-differentiated Neuroendocrine Tumor

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: AC Camargo Cancer Center | Conditions: Neuroendocrine Tumors, Progesterone Receptor Positive Tumor | Phase 2 | Status: COMPLETED